Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \<70 mg/dL by increasing statin and/or LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.
Male or female >18 years of age
Receive follow-up care with Intermountain Health
Value-based patient (as defined in the EDW)
Coronary artery disease (Primary inpatient CAD diagnosis during index encounter; Primary inpatient MI diagnosis during index encounter; PCI during index encounter; or CABG during index encounter
Patient age <18 years.
Receipt of or expected receipt of palliative care, expected discharge to hospice, or long-term care facility (i.e., skilled nursing facility).
Pregnant or lactating women
Parallel
Clinical Pharmacy Team
Other interventionPatients will receive targeted care of their LDL-C through a pharmacist-driven management program.
Usual Care
Other interventionPatient will receive usual care for their LDL-C management.
Proportion of patients who achieve an LDL-C <70 mg/dL by 1-year.
Click on the lead sponsor to view all of their trials.
